Cargando…

HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway

BACKGROUND: Pediatric high-grade gliomas (pHGGs) are an aggressive CNS tumor which are often characterized by mutations in H3F3A, the gene that encodes Histone H3.3 (H3.3). A substitution of the Glycine at position 34 of H3.3 with either Arginine or Valine (H3.3G34R/V), was recently described in a l...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdallah, Aalaa, Cardona, Herminio, Gadd, Samantha, Brat, Daniel, Picketts, David, Becher, Oren, Li, Xiao-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164885/
http://dx.doi.org/10.1093/neuonc/noac079.217
_version_ 1784720251489878016
author Abdallah, Aalaa
Cardona, Herminio
Gadd, Samantha
Brat, Daniel
Picketts, David
Becher, Oren
Li, Xiao-Nan
author_facet Abdallah, Aalaa
Cardona, Herminio
Gadd, Samantha
Brat, Daniel
Picketts, David
Becher, Oren
Li, Xiao-Nan
author_sort Abdallah, Aalaa
collection PubMed
description BACKGROUND: Pediatric high-grade gliomas (pHGGs) are an aggressive CNS tumor which are often characterized by mutations in H3F3A, the gene that encodes Histone H3.3 (H3.3). A substitution of the Glycine at position 34 of H3.3 with either Arginine or Valine (H3.3G34R/V), was recently described in a large cohort of pHGG samples and has been characterized as occurring in anywhere between 5-20% of pHGGs. Attempts to study the mechanisms of H3.3G34R have proven difficult due to the developmental nature of the disease and the requirement of co-occurring mutations for model development. METHODS: We utilized the RCAS system to develop a genetically engineered mouse model (GEMM) that incorporates PDGF-A activation, TP53 loss and the H3.3G34R mutation both in the context of ATRX loss and ATRX presence in nestin expressing progenitors. RESULTS: We show that in H3.3G34R expressing mice, ATRX loss significantly increased tumor latency from 90 days to 143 days (p < 0.01, Log rank test) and decreased tumor incidence from 81% to 57% (p < 0.01, Fisher’s exact test). By contrast, H3.3G34R did not significantly impact tumor latency in either our ATRX loss (163 days to 143 days, p = 0.178, Log-rank test) or our ATRX expressing (95 days to 90 days, p = 0.415, Log-rank test) models. Transcriptomic analysis revealed that ATRX loss in the context of H3.3G34R upregulates the PRC2 associated genes Hoxa2, Hoxa3, Hoxa5, and Hoxa7 (p < 0.05, unpaired t-test). GSEA analysis and RT-qPCR data suggest that ATRX loss works synergistically with H3.3G34R to promote NOTCH pathway activation through upregulation of the NOTCH ligand Dll3 (p < 0.01, unpaired t-test). CONCLUSIONS: Our study proposes a model in which ATRX loss is the major contributor to transcriptomic changes in the majority of H3.3G34R pHGGs. Broadly, our work highlights the importance of studying mechanisms of co-occurring genetic events separately and in combination.
format Online
Article
Text
id pubmed-9164885
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91648852022-06-05 HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway Abdallah, Aalaa Cardona, Herminio Gadd, Samantha Brat, Daniel Picketts, David Becher, Oren Li, Xiao-Nan Neuro Oncol High Grade Glioma BACKGROUND: Pediatric high-grade gliomas (pHGGs) are an aggressive CNS tumor which are often characterized by mutations in H3F3A, the gene that encodes Histone H3.3 (H3.3). A substitution of the Glycine at position 34 of H3.3 with either Arginine or Valine (H3.3G34R/V), was recently described in a large cohort of pHGG samples and has been characterized as occurring in anywhere between 5-20% of pHGGs. Attempts to study the mechanisms of H3.3G34R have proven difficult due to the developmental nature of the disease and the requirement of co-occurring mutations for model development. METHODS: We utilized the RCAS system to develop a genetically engineered mouse model (GEMM) that incorporates PDGF-A activation, TP53 loss and the H3.3G34R mutation both in the context of ATRX loss and ATRX presence in nestin expressing progenitors. RESULTS: We show that in H3.3G34R expressing mice, ATRX loss significantly increased tumor latency from 90 days to 143 days (p < 0.01, Log rank test) and decreased tumor incidence from 81% to 57% (p < 0.01, Fisher’s exact test). By contrast, H3.3G34R did not significantly impact tumor latency in either our ATRX loss (163 days to 143 days, p = 0.178, Log-rank test) or our ATRX expressing (95 days to 90 days, p = 0.415, Log-rank test) models. Transcriptomic analysis revealed that ATRX loss in the context of H3.3G34R upregulates the PRC2 associated genes Hoxa2, Hoxa3, Hoxa5, and Hoxa7 (p < 0.05, unpaired t-test). GSEA analysis and RT-qPCR data suggest that ATRX loss works synergistically with H3.3G34R to promote NOTCH pathway activation through upregulation of the NOTCH ligand Dll3 (p < 0.01, unpaired t-test). CONCLUSIONS: Our study proposes a model in which ATRX loss is the major contributor to transcriptomic changes in the majority of H3.3G34R pHGGs. Broadly, our work highlights the importance of studying mechanisms of co-occurring genetic events separately and in combination. Oxford University Press 2022-06-03 /pmc/articles/PMC9164885/ http://dx.doi.org/10.1093/neuonc/noac079.217 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle High Grade Glioma
Abdallah, Aalaa
Cardona, Herminio
Gadd, Samantha
Brat, Daniel
Picketts, David
Becher, Oren
Li, Xiao-Nan
HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway
title HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway
title_full HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway
title_fullStr HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway
title_full_unstemmed HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway
title_short HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway
title_sort hgg-01. a novel genetically engineered h3.3g34r model reveals cooperation with atrx loss in upregulation of prc2 target genes and promotion of the notch pathway
topic High Grade Glioma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164885/
http://dx.doi.org/10.1093/neuonc/noac079.217
work_keys_str_mv AT abdallahaalaa hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway
AT cardonaherminio hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway
AT gaddsamantha hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway
AT bratdaniel hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway
AT pickettsdavid hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway
AT becheroren hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway
AT lixiaonan hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway